Back to News
Market Impact: 0.2
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Source: globenewswire.com
Healthcare & BiotechCompany FundamentalsProduct Launches
ATTO-1310 showed preliminary clinical proof-of-concept in chronic pruritus and high-itch atopic dermatitis (AD), supporting the program’s early efficacy signal. The company expects complete Phase 1b data in Q4 2026, extending the timeline for catalysts and keeping near-term upside modest.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- U.S. diesel prices are now 60% higher than they were before the Iran war, with one Trump voter paying twice as much to fuel his farm equipment
- Wall Street analysts warns the AI boom is on ‘borrowed time'
- Dell Booked More AI Server Orders in 3 Months Than It Recorded in Total Revenue
- Hyundai Motor to roll out in-house driver-assist system in 2029
- Larry Ellison cancels plan to sell Oracle stock
- Oracle’s Ellison cancels plan to sell up to 50 mln shares